NASDAQ: $ABCL A New Frontier in Dermatology Treatment AbCellera has officially announced positive top-line results from its Phase 2 clinical trial evaluating ABCL635, a potential therapeutic candidate for the treatment of moderate-to-severe atopic dermatitis. This development marks a significant milestone for the company as it advances its pipeline of antibody-based therapies. Key Trial Findings The…